Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine
Shares Up 42% Following Unexplained Outbreaks
The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.
You may also be interested in...
As three big players get set to reveal pivotal data for adult RSV vaccines, Bavarian Nordic seals a deal for its candidate that could still claim a sizeable niche if a late-stage trial delivers.
The UK biotech looks to have reached the end of the road, despite some encouraging signs from its microbiome-based pipeline.
CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.